

Frédéric HAMMEL



Fred Hammel is the CEO of TxCell, a biotechnology company dedicated to the development of new therapeutic treatments for auto-immune diseases. Fred has more than 15 years of experience in life science innovations.

Before joining TxCell, Fred was General Manager of the Soluscope Group, a private company developing and manufacturing innovative medical devices. He promoted sales in more than 20 countries with a dominant market share, competing with worldwide leaders.

Previously Fred was Research and Development director at the “Infection Control” business unit of Air Liquid Healthcare.

Fred started his industrial career in Rhone Poulenc Rorer (RPR) as manufacturing director. He designed & launched the manufacturing unit of a lead injectable product. Then he designed & launched a clinical manufacturing facility for Gene and Cell therapy products.

Fred has a strong scientific background. He followed 2 masters of Biology at the French “Ecole Normale Supérieure”, then he followed a MBA at the “College des Ingenieurs” in Paris.